1. 536 RANIDO trial: Racotumomab-alum vaccine, Nimotuzumab or Docetaxel as switch maintenance therapy for advanced NSCLC. (September 2015) Authors: Hernandez, M.; Neninger, E.; Santiesteban, E.; Ortiz, R.; Amador, R.; Bello, L.; Acosta, S.; Flores, Y.; Cala, M.; Martínez, O.; Calana, A.; Pichs, G.; Robaina, M.; Sánchez, L.; Viada, C.; Valdez, A.; Mendoza, I.; Guerra, P.; Crombet, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗